Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease

2009, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), Kidney Int Suppl, 113, S1 Moe, 2006, Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 69, 1945, 10.1038/sj.ki.5000414 Lui, 1943, Studies in calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T. 10) and iron, Medicine, 22, 103, 10.1097/00005792-194305000-00002 Ott, 2008, Histomorphometric measurements of bone turnover, mineralization, and volume, Clin J Am Soc Nephrol, 3, S151, 10.2215/CJN.04301206 Cozzolino, 2014, Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?, Nephrol Dial Transplant, 10.1093/ndt/gft514 Goldsmith, 2010, Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) guidelines: a European Renal Best Practice (ERBP) commentary statement, Nephrol Dial Transplant, 25, 3823, 10.1093/ndt/gfq513 Lucas, 1883, Form of late rickets associated with albuminuria, rickets of adolescents, Lancet, 1, 993, 10.1016/S0140-6736(02)37965-0 MacCallum, 1905, Tumor of the parathyroid gland, John Hopkins Hosp Bull, 16, 87 Langmead, 1933, Renal rickets associated with parathyroid hyperplasia, Arch Dis Child, 8, 265, 10.1136/adc.8.46.265 Llach, 2000, Renal osteodystrophies, 2103 Cohen-Solal, 1992, Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?, Bone, 13, 1, 10.1016/8756-3282(92)90354-Y Cannata-Andia, 1998, Hypokinetic azotemic osteodystrophy, Kidney Int, 54, 1000, 10.1046/j.1523-1755.1998.00080.x Cannata-Andia, 2013, Osteoporosis and adynamic bone in chronic kidney disease, J Nephrol, 26, 73, 10.5301/jn.5000212 Sherrard, 1996, The aplastic form of renal osteodystrophy, Nephrol Dial Transplant, 11, 29, 10.1093/ndt/11.supp3.29 Brandenburg, 2008, Adynamic bone disease-bone and beyond, NDT Plus, 3, 135 Frazao, 2009, Adynamic bone disease: clinical and therapeutic implications, Curr Opin Nephrol Hypertens, 18, 303, 10.1097/MNH.0b013e32832c4df0 Hercz, 1993, Aplastic osteodystrophy without aluminum: the role of “suppressed” parathyroid function, Kidney Int, 44, 860, 10.1038/ki.1993.323 Rocha, 2006, Variant of adynamic bone disease in hemodialysis patients: fact or fiction?, Am J Kidney Dis, 48, 430, 10.1053/j.ajkd.2006.05.028 Urena, 2014, When, how, and why a bone biopsy should be performed in patients with chronic kidney disease (CKD)?, Semin Nephrol, 34, 612, 10.1016/j.semnephrol.2014.09.004 Parfitt, 2003, Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry, Curr Opin Nephrol Hypertens, 12, 387, 10.1097/00041552-200307000-00007 Andress, 2008, Adynamic bone in patients with chronic kidney disease, Kidney Int, 73, 1345, 10.1038/ki.2008.60 Asci, 2011, The link between bone and coronary calcifications in CKD-5 patients on haemodialysis, Nephrol Dial Transplant, 26, 1010, 10.1093/ndt/gfq491 Ferreira, 2008, Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients, J Am Soc Nephrol, 19, 405, 10.1681/ASN.2006101089 Lobao, 2004, High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis, Clin Nephrol, 62, 432, 10.5414/CNP62432 Sherrard, 1993, The spectrum of bone disease in end-stage renal failure--an evolving disorder, Kidney Int, 43, 436, 10.1038/ki.1993.64 Spasovski, 2007, Low turn-over bone disease in patients with chronic renal disease, Med Pregl, 60, 21 Spasovski, 2003, Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis, Nephrol Dial Transplant, 18, 1159, 10.1093/ndt/gfg116 Torres, 1995, Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH, Kidney Int, 47, 1434, 10.1038/ki.1995.201 Malluche, 2004, The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?, Nephrol Dial Transplant, 19, i9, 10.1093/ndt/gfh1002 Malluche, 2011, Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients, J Bone Miner Res, 26, 1368, 10.1002/jbmr.309 Tomiyama, 2010, Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment, J Bone Miner Res, 25, 499, 10.1359/jbmr.090735 Tsukamoto, 2012, Kidney and bone update: the 5-year history and future of CKD-MBD. Bone biopsy and histomorphometrical analysis, Clin Calcium, 22, 1019 Morrow, 2012, Specific bone and mineral disorders in patients with cronic kidney disease, Clin Ref Bone Miner Metab, 10, 184, 10.1007/s12018-011-9114-6 Jorgetti, 2000, Different patterns of renal osteodystrophy in Iberoamerica, Am J Med Sci, 320, 76, 10.1097/00000441-200008000-00002 Monier-Faugere, 1996, Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients, Nephrol Dial Transplant, 11, 111, 10.1093/ndt/11.supp3.111 Moore, 2009, Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients, Clin J Am Soc Nephrol, 4, 1484, 10.2215/CJN.01770408 Hernandez, 1994, Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis, Nephrol Dial Transplant, 9, 517, 10.1093/ndt/9.5.517 Spasovski, 2009, Strategies to manage low-bone turnover, Nefrologia, 29, 295 Bover, 2011, Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation, Kidney Int, 1, 122, 10.1038/kisup.2011.28 Bover, 1994, The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia, Kidney Int, 46, 310, 10.1038/ki.1994.276 Massry, 1973, Excretion of phosphate and calcium. Physiology of their renal handling and relation to clinical medicine, Arch Intern Med, 131, 828, 10.1001/archinte.1973.00320120068006 Bover, 1999, Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus, Bone, 25, 279, 10.1016/S8756-3282(99)00169-6 Coen, 2005, Adynamic bone disease: an update and overview, J Nephrol, 18, 117 Divieti, 2002, Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor, Endocrinology, 143, 171, 10.1210/endo.143.1.8575 Kazama, 2003, [Renal bone disease and osteoprotegerin], Clin Calcium, 13, 311 Reichel, 1993, Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism, Kidney Int, 44, 1259, 10.1038/ki.1993.377 Slatopolsky, 2000, A novel mechanism for skeletal resistance in uremia, Kidney Int, 58, 753, 10.1016/S0085-2538(15)47156-X Urena, 1994, The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure, Kidney Int, 45, 605, 10.1038/ki.1994.79 Xie, 1996, Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells, Am J Physiol, 270, E654 Sawaya, 2002, Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism, Clin Nephrol, 57, 51, 10.5414/CNP57051 Wesseling-Perry, 2010, The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84), J Clin Endocrinol Metab, 95, 2772, 10.1210/jc.2009-1909 Bover, 1994, Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat, Kidney Int, 45, 953, 10.1038/ki.1994.129 Drueke, 2013, Report on 2012 ISN Nexus symposium: ‘bone and the kidney’, Kidney Int, 83, 557, 10.1038/ki.2012.453 Fang, 2014, Early chronic kidney disease-mineral bone disorder stimulates vascular calcification, Kidney Int, 85, 142, 10.1038/ki.2013.271 Mathew, 2006, Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease, Eur J Clin Invest, 36, 43, 10.1111/j.1365-2362.2006.01663.x Goodman, 1994, Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy, Kidney Int, 46, 1160, 10.1038/ki.1994.380 Andress, 1989, Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism, Kidney Int, 36, 471, 10.1038/ki.1989.219 Barreto, 2008, Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study, Am J Kidney Dis, 52, 1139, 10.1053/j.ajkd.2008.06.024 Delanaye, 2014, Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts, Nephrol Dial Transplant, 29, 997, 10.1093/ndt/gft275 Mac, 2012, Pathophysiology of chronic kidney disease-mineral and bone disorder, Joint Bone Spine, 79, 544, 10.1016/j.jbspin.2012.09.014 Pelletier, 2013, The relation between renal function and serum sclerostin in adult patients with CKD, Clin J Am Soc Nephrol, 8, 819, 10.2215/CJN.07670712 Andress, 1991, Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma, Kidney Int, 39, 942, 10.1038/ki.1991.118 Davies, 2005, Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome, J Am Soc Nephrol, 16, 917, 10.1681/ASN.2004100835 Lund, 2004, Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model, J Am Soc Nephrol, 15, 359, 10.1097/01.ASN.0000109671.99498.08 Babij, 2003, High bone mass in mice expressing a mutant LRP5 gene, J Bone Miner Res, 18, 960, 10.1359/jbmr.2003.18.6.960 Fang, 2014, CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder, J Am Soc Nephrol, 25, 1760, 10.1681/ASN.2013080818 Baron, 2007, Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton, Endocrinology, 148, 2635, 10.1210/en.2007-0270 Ferreira, 2013, Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?, PLoS One, 8, e79721, 10.1371/journal.pone.0079721 Pereira, 2009, Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease, Bone, 45, 1161, 10.1016/j.bone.2009.08.008 Lu, 2011, The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment, J Bone Miner Res, 26, 331, 10.1002/jbmr.226 Tagliabracci, 2014, Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis, Proc Natl Acad Sci U S A, 111, 5520, 10.1073/pnas.1402218111 Cejka, 2011, Sclerostin and Dickkopf-1 in renal osteodystrophy, Clin J Am Soc Nephrol, 6, 877, 10.2215/CJN.06550810 Kramer, 2010, Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice, J Bone Miner Res, 25, 178, 10.1359/jbmr.090730 Li, 2014, The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b, J Bone Miner Res, 29, 43, 10.1002/jbmr.2044 Sabbagh, 2012, Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy, J Bone Miner Res, 27, 1757, 10.1002/jbmr.1630 Vervloet, 2014, Bone: a new endocrine organ at the heart of chronic kidney disease and mineral disorders, Lancet Diabetes Endocrinol, 2, 427, 10.1016/S2213-8587(14)70059-2 Thambiah, 2012, Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness, Calcif Tissue Int, 90, 473, 10.1007/s00223-012-9595-4 Ardawi, 2011, Determinants of serum sclerostin in healthy pre- and postmenopausal women, J Bone Miner Res, 26, 2812, 10.1002/jbmr.479 Drueke, 2011, Sclerostin: just one more player in renal bone disease?, Clin J Am Soc Nephrol, 6, 700, 10.2215/CJN.01370211 Jean, 2013, Sclerostin in CKD-MBD: one more paradoxical bone protein?, Nephrol Dial Transplant, 28, 2932, 10.1093/ndt/gft222 Modder, 2011, Relation of age, gender, and bone mass to circulating sclerostin levels in women and men, J Bone Miner Res, 26, 373, 10.1002/jbmr.217 Cejka, 2012, Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients, Nephrol Dial Transplant, 27, 226, 10.1093/ndt/gfr270 Viaene, 2013, Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?, Nephrol Dial Transplant, 28, 3024, 10.1093/ndt/gft039 Goldsmith, 2014, The uses and abuses of vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD), Semin Nephrol, 34, 660, 10.1016/j.semnephrol.2014.10.002 Huttunen, 2007, High dietary phosphate intake reduces bone strength in the growing rat skeleton, J Bone Miner Res, 22, 83, 10.1359/jbmr.061009 Lau, 2013, High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease, Nephrol Dial Transplant, 28, 62, 10.1093/ndt/gfs333 Mathew, 2007, Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy, J Am Soc Nephrol, 18, 122, 10.1681/ASN.2006050490 Slatopolsky, 1971, On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog, J Clin Invest, 50, 492, 10.1172/JCI106517 Stubbs, 2012, Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease, J Bone Miner Res, 27, 38, 10.1002/jbmr.516 Jara, 1995, Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure, Kidney Int, 47, 1746, 10.1038/ki.1995.241 Tanaka, 2009, The impact of diabetes mellitus on vitamin D metabolism in predialysis patients, Bone, 45, 949, 10.1016/j.bone.2009.07.016 Muras, 2013, Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease, J Clin Endocrinol Metab, 98, E1901, 10.1210/jc.2013-2418 Yamamoto, 2001, Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy, Am J Kidney Dis, 38, S161, 10.1053/ajkd.2001.27428 Garcia-Martin, 2012, Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus, J Clin Endocrinol Metab, 97, 234, 10.1210/jc.2011-2186 Gennari, 2012, Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes, J Clin Endocrinol Metab, 97, 1737, 10.1210/jc.2011-2958 Freedman, 2009, Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study, J Bone Miner Res, 24, 1719, 10.1359/jbmr.090501 Bover, 2012, Role of vitamin D receptor activators in peritoneal dialysis, Contrib Nephrol, 178, 124, 10.1159/000337832 Sánchez-M, 2000, Parathormone secretion in peritoneal dialysis patients with adynamic bone disease, Am J Kidney Dis, 36, 953, 10.1053/ajkd.2000.19093 Couttenye, 1997, High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population, Nephrol Dial Transplant, 12, 2144, 10.1093/ndt/12.10.2144 Dukkipati, 2010, Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients, J Ren Nutr, 20, 243, 10.1053/j.jrn.2009.10.006 Perouse de, 2014, Online hemodiafiltration in children and hypoparathyroidism: a single-centre series of cases, Nephrol Ther, 10, 35 Mazzaferro, 2008, Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients, Nephrol Dial Transplant, 23, 2319, 10.1093/ndt/gfm931 Yajima, 2001, Development of low-turnover bone diseases after parathyroidectomy and autotransplantation, Int J Urol, 8, S76, 10.1046/j.1442-2042.2001.00340.x Konstantinidis, 2013, Utilization of parathyroidectomy for secondary hyperparathyroidism in end stage renal disease, Clin Kidney J, 6, 277, 10.1093/ckj/sft028 Kestenbaum, 2004, Survival following parathyroidectomy among United States dialysis patients, Kidney Int, 66, 2010, 10.1111/j.1523-1755.2004.00972.x Kaye, 1993, Long-term outcome following total parathyroidectomy in patients with end-stage renal disease, Clin Nephrol, 39, 192 de Francisco, 2002, Parathyroidectomy in dialysis patients, Kidney Int Suppl, 80, 161, 10.1046/j.1523-1755.61.s80.27.x Jofre, 2003, Parathyroidectomy: whom and when?, Kidney Int Suppl, 85, S97, 10.1046/j.1523-1755.63.s85.23.x Moorthi, 2013, Recent advances in the noninvasive diagnosis of renal osteodystrophy, Kidney Int, 84, 886, 10.1038/ki.2013.254 Brandenburg V, Krüger T. Special issues in renal osteodystrophy, ROD: survey results. 2014. Available: http://ndt-educational.org/rod.html. Accessed: April 30, 2014. Trombetti, 2013, Alterations of bone microstructure and strength in end-stage renal failure, Osteoporos Int, 24, 1721, 10.1007/s00198-012-2133-4 Souberbielle, 2006, Inter-method variability in PTH measurement: implication for the care of CKD patients, Kidney Int, 70, 345, 10.1038/sj.ki.5001606 Souberbielle, 2010, Parathyroid hormone measurement in CKD, Kidney Int, 77, 93, 10.1038/ki.2009.374 Barreto, 2008, K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients, Kidney Int, 73, 771, 10.1038/sj.ki.5002769 Urena, 1999, Circulating biochemical markers of bone remodeling in uremic patients, Kidney Int, 55, 2141, 10.1046/j.1523-1755.1999.00461.x Couttenye, 1996, Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients, Nephrol Dial Transplant, 11, 1065, 10.1093/oxfordjournals.ndt.a027457 Urena, 1996, Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients, J Am Soc Nephrol, 7, 506, 10.1681/ASN.V73506 Lehmann, 2008, Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5, Clin Nephrol, 70, 296, 10.5414/CNP70296 Monier-Faugere, 2001, Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients, Kidney Int, 60, 1460, 10.1046/j.1523-1755.2001.00949.x Coen, 2002, Serum osteoprotegerin and renal osteodystrophy, Nephrol Dial Transplant, 17, 233, 10.1093/ndt/17.2.233 Fehmi, 2009, Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio, Clin Nephrol, 71, 267, 10.5414/CNP71267 Herberth, 2010, Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study, Am J Kidney Dis, 55, 897, 10.1053/j.ajkd.2009.12.041 Sprague, 2013, Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients?, Clin J Am Soc Nephrol, 8, 321, 10.2215/CJN.10331012 Garrett, 2013, PTH--a particularly tricky hormone: why measure it at all in kidney patients?, Clin J Am Soc Nephrol, 8, 299, 10.2215/CJN.09580911 Sardiwal, 2013, Bone alkaline phosphatase in CKD-mineral bone disorder, Am J Kidney Dis, 62, 810, 10.1053/j.ajkd.2013.02.366 Mazzaferro, 2014, News on biomarkers in CKD-MBD, Semin Nephrol, 34, 599, 10.1016/j.semnephrol.2014.09.006 de Oliveira, 2011, Sociedade Brasileira de Nefrologia. Adynamic bone disease, J Bras Nefrol, 33, 209 Drueke, 1995, The pathogenesis of parathyroid gland hyperplasia in chronic renal failure, Kidney Int, 48, 259, 10.1038/ki.1995.292 Piraino, 1988, Fractures and vertebral bone mineral density in patients with renal osteodystrophy, Clin Nephrol, 30, 57 Kurz, 1994, Evidence for abnormal calcium homeostasis in patients with adynamic bone disease, Kidney Int, 46, 855, 10.1038/ki.1994.342 London, 2012, Bone-vascular cross-talk, J Nephrol, 25, 619, 10.5301/jn.5000187 Malluche, 2012, Differences in bone quality in low- and high-turnover renal osteodystrophy, J Am Soc Nephrol, 23, 525, 10.1681/ASN.2010121253 Floege, 2011, Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population, Nephrol Dial Transplant, 26, 1948, 10.1093/ndt/gfq219 Ganesh, 2001, Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients, J Am Soc Nephrol, 12, 2131, 10.1681/ASN.V12102131 Kalantar-Zadeh, 2006, Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients, Kidney Int, 70, 771, 10.1038/sj.ki.5001514 Naves-Diaz, 2011, Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study, Nephrol Dial Transplant, 26, 1938, 10.1093/ndt/gfq304 Stevens, 2004, Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes, J Am Soc Nephrol, 15, 770, 10.1097/01.ASN.0000113243.24155.2F Block, 2004, Mineral metabolism, mortality, and morbidity in maintenance hemodialysis, J Am Soc Nephrol, 15, 2208, 10.1097/01.ASN.0000133041.27682.A2 Tentori, 2008, Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS), Am J Kidney Dis, 52, 519, 10.1053/j.ajkd.2008.03.020 Jean, 2011, Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study, Nephron Clin Pract, 118, c204, 10.1159/000321507 Qunibi, 2011, Target levels for serum phosphorus and parathyroid hormone, Semin Dial, 24, 29, 10.1111/j.1525-139X.2010.00823.x Qunibi WY, Henrich WL. Adynamic bone disease associated with chronic kidney disease. Available: http://www.uptodate.com/contents/adynamic-bone-disease-associated-with-chronic-kidney-disease?source=search_result&search=adynamic+bone&selectedTitle=1~25. Accessed: April 30, 2014. Torregrosa, 2011, Spanish Nephrology Society. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.), Nefrologia, 31 2008, Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients, Ther Apher Dial, 12, 514, 10.1111/j.1744-9987.2008.00648.x Atsumi, 1999, Risk factors for vertebral fractures in renal osteodystrophy, Am J Kidney Dis, 33, 287, 10.1016/S0272-6386(99)70302-1 Coco, 2000, Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone, Am J Kidney Dis, 36, 1115, 10.1053/ajkd.2000.19812 Danese, 2006, PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis, Am J Kidney Dis, 47, 149, 10.1053/j.ajkd.2005.09.024 Ho, 2013, Women and CKD-mineral and bone disorder, Adv Chronic Kidney Dis, 20, 423, 10.1053/j.ackd.2013.06.007 Iimori, 2012, Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study, Nephrol Dial Transplant, 27, 345, 10.1093/ndt/gfr317 Bilezikian, 2001, Therapy of male osteoporosis with parathyroid hormone, Calcif Tissue Int, 69, 248, 10.1007/s00223-001-1041-y Duan, 1999, Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone, J Clin Endocrinol Metab, 84, 718, 10.1210/jcem.84.2.5498 Jamal, 2012, Bone and kidney disease: diagnostic and therapeutic implications, Curr Rheumatol Rep, 14, 217, 10.1007/s11926-012-0243-9 Barreto, 2006, Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem, Kidney Int, 69, 1852, 10.1038/sj.ki.5000311 Taal, 2003, Total hip bone mass predicts survival in chronic hemodialysis patients, Kidney Int, 63, 1116, 10.1046/j.1523-1755.2003.00837.x London, 2004, Arterial calcifications and bone histomorphometry in end-stage renal disease, J Am Soc Nephrol, 15, 1943, 10.1097/01.ASN.0000129337.50739.48 London, 2008, Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD, J Am Soc Nephrol, 19, 1827, 10.1681/ASN.2007050622 Rhee, 2012, Persistently low intact parathyroid hormone levels predict a progression of aortic arch calcification in incident hemodialysis patients, Clin Exp Nephrol, 16, 433, 10.1007/s10157-011-0577-z Hill, 2013, Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease, Kidney Int, 83, 959, 10.1038/ki.2012.403 Spiegel, 2012, Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets, Kidney Int, 81, 1116, 10.1038/ki.2011.490 London, 2010, The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification, Clin Nephrol, 74, 423 Massy, 2013, Vascular calcification, Curr Opin Nephrol Hypertens, 22, 405, 10.1097/MNH.0b013e328362155b Adragao, 2009, Low bone volume--a risk factor for coronary calcifications in hemodialysis patients, Clin J Am Soc Nephrol, 4, 450, 10.2215/CJN.01870408 Coen, 2007, Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?, Nephrol Dial Transplant, 22, 3262, 10.1093/ndt/gfm370 Coen, 2009, Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study, Am J Nephrol, 29, 145, 10.1159/000151769 Caira, 2006, Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation, J Am Coll Cardiol, 47, 1707, 10.1016/j.jacc.2006.02.040 Zhu, 2011, The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells, PLoS One, 6, e19595, 10.1371/journal.pone.0019595 Shao, 2005, Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals, J Clin Invest, 115, 1210, 10.1172/JCI24140 Haris, 2006, Reversal of adynamic bone disease by lowering of dialysate calcium, Kidney Int, 70, 931, 10.1038/sj.ki.5001666 Malluche, 2008, Effects of treatment of renal osteodystrophy on bone histology, Clin J Am Soc Nephrol, 3, S157, 10.2215/CJN.02500607 Iwata, 2007, Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels, Intern Med, 46, 447, 10.2169/internalmedicine.46.6338 Shigematsu, 2011, Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia, Ther Apher Dial, 15, 176, 10.1111/j.1744-9987.2010.00898.x Yajima, 2013, Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease, Ther Apher Dial, 17, 41, 10.1111/1744-9987.12038 Chertow, 2002, Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients, Kidney Int, 62, 245, 10.1046/j.1523-1755.2002.00434.x Di Iorio, 2013, Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial, Am J Kidney Dis, 62, 771, 10.1053/j.ajkd.2013.03.023 Jamal, 2013, Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis, Lancet, 382, 1268, 10.1016/S0140-6736(13)60897-1 Jean, 2011, Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study, Hemodial Int, 15, 485, 10.1111/j.1542-4758.2011.00575.x Qunibi, 2008, A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study, Am J Kidney Dis, 51, 952, 10.1053/j.ajkd.2008.02.298 St Peter, 2008, A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data, Am J Kidney Dis, 51, 445, 10.1053/j.ajkd.2007.12.002 Suki, 2007, Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients, Kidney Int, 72, 1130, 10.1038/sj.ki.5002466 Cozzolino, 2012, VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH </= 150 pg/mL: results of the Italian FARO Survey, Nephrol Dial Transplant, 27, 3588, 10.1093/ndt/gfs108 Heaf, 2012, Vitamin d and stage 5 chronic kidney disease: a new paradigm?, Semin Dial, 25, 50, 10.1111/j.1525-139X.2011.00986.x Lee, 2007, Impact of kidney bone disease and its management on survival of patients on dialysis, J Ren Nutr, 17, 38, 10.1053/j.jrn.2006.07.006 Teng, 2005, Activated injectable vitamin D and hemodialysis survival: a historical cohort study, J Am Soc Nephrol, 16, 1115, 10.1681/ASN.2004070573 Holliday, 2000, 1,25-Dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro, J Am Soc Nephrol, 11, 1857, 10.1681/ASN.V11101857 Nakane, 2007, Differential effects of Vitamin D analogs on calcium transport, J Steroid Biochem Mol Biol, 103, 84, 10.1016/j.jsbmb.2006.07.004 Monier-Faugere, 2007, Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease, Clin J Am Soc Nephrol, 2, 1255, 10.2215/CJN.03461006 Amerling, 2010, Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series, Blood Purif, 29, 293, 10.1159/000276666 Ott, 2012, Bisphosphonate safety and efficacy in chronic kidney disease, Kidney Int, 82, 833, 10.1038/ki.2012.253 Ott, 2013, Therapy for patients with CKD and low bone mineral density, Nat Rev Nephrol, 9, 681, 10.1038/nrneph.2013.182 Torregrosa, 2012, Successful treatment of calcific uraemic arteriolopathy with bisphosphonates, Nefrologia, 32, 329 Torregrosa, 2013, Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates, Clin Nephrol, 10.5414/CN107923 Monney, 2004, Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure, Nephrol Dial Transplant, 19, 2130, 10.1093/ndt/gfh305 Price, 2002, The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption, Calcif Tissue Int, 71, 356, 10.1007/s00223-002-1006-9 Shiraishi, 2006, Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium, Am J Kidney Dis, 48, 151, 10.1053/j.ajkd.2006.04.062 Nemeth, 2002, The search for calcium receptor antagonists (calcilytics), J Mol Endocrinol, 29, 15, 10.1677/jme.0.0290015 Demirci, 2009, The influence of dialysate calcium on progression of arterial stiffness in peritoneal dialysis patients, Perit Dial Int, 29, S15, 10.1177/089686080902902S02 Liang, 2014, Association of dialysate calcium concentration with fetuin a level and carotid intima-media thickness in peritoneal dialysis patients, Ren Fail, 36, 65, 10.3109/0886022X.2013.832309 Fujimori, 2007, Low-calcium dialysate improves mineral metabolism in hemodialysis patients, Clin Nephrol, 67, 20, 10.5414/CNP67020 Lezaic, 2007, Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study, Ther Apher Dial, 11, 121, 10.1111/j.1744-9987.2007.00419.x Spasovski, 2007, Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium, Bone, 41, 698, 10.1016/j.bone.2007.06.014 Ok, 2008, Reduction of calcium exposure slows down progression of vascular calcification and improves adynamic bone disease [abstract], Clin J Am Soc Nephrol, 3 Cejka, 2010, Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1-34)): a pilot study, Kidney Blood Press Res, 33, 221, 10.1159/000316708 Jamal, 2011, Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues?, Semin Dial, 24, 12, 10.1111/j.1525-139X.2010.00817.x Torregrosa, 2005, Definitive treatment for persistent hypoparathyroidism in a kidney transplant patient: parathyroid allotransplantation, Thyroid, 15, 1299, 10.1089/thy.2005.15.1299 Bover, 2005, [New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics], Nefrologia, 25, 109 Ayasreh, 2012, Recombinant PTH associated with hypercalcaemia and renal failure, Clin Kidney J, 6, 93, 10.1093/ckj/sfs148 Lems, 2014, Established and forthcoming drugs for the treatment of osteoporosis, Curr Opin Rheumatol, 26, 245, 10.1097/BOR.0000000000000057